CG Oncology (CGON)

• Market cap: $5.18B
• 1 day: -0.95%
• 5 days: 10.43%
• 1 month: 19.99%
• 3 months: 46.84%
• 6 months: 83.12%
• Year to date: 46.66%
• 1 year: 134.02%
• 5 years: 64.89%
• 10 years: 64.89%
• Sector: Healthcare
• Industry: Biotechnology

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 113